BEVERLY, Mass., July 13, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX), today announced, it has successfully completed a series of animal model tests on two multi-drug resistant non-small-cell lung carcinoma human cell lines, A549 and NCI-H1975, using its proprietary pharmaceutical compound Kevetrin(tm). In each cell line, tumor volume was reduced by more than 90% and tumor growth was delayed by more than 100%. In addition, both the tumor volume reduction and the tumor growth delay were greater in each cell line with Kevetrin than with paclitaxel (brand name Taxol(r)) (p<0.01). Each experiment was repeated in order to increase the level of confidence in the results. The results in the repeated experiments were similar to those in the initial tests.
